MedPath

A Study to Assess How Well Certolizumab Pegol Works in Patients With Moderate to Severe Plaque Psoriasis as Part of Routine Clinical Practice

Completed
Conditions
Plaque Psoriasis
Interventions
Registration Number
NCT04053881
Lead Sponsor
UCB Biopharma SRL
Brief Summary

The purpose of the study is to assess the effectiveness of certolizumab pegol in patients with moderate to severe plaque psoriasis as part of routine clinical practice.

Detailed Description

Not available

Recruitment & Eligibility

Status
COMPLETED
Sex
All
Target Recruitment
412
Inclusion Criteria
  • The patient is ≥18 years of age at observational point 1
  • The patient must have a clinical diagnosis of moderate to severe Plaque psoriasis according to the diagnostic criteria used by the physician in routine clinical practice
  • The patient has an available PASI assessment prior to the first certolizumab pegol dose according to the standard of care
  • The patient must be newly prescribed with certolizumab pegol
  • If a patient is participating in an ongoing investigational study, then he/she will not be able to take part in this study
Exclusion Criteria

Not applicable

Study & Design

Study Type
OBSERVATIONAL
Study Design
Not specified
Arm && Interventions
GroupInterventionDescription
Certolizumab pegolCertolizumab pegolPlaque psoriasis patients who have been newly prescribed certolizumab pegol (CZP).
Primary Outcome Measures
NameTimeMethod
Percentage of patients achieving Psoriasis Area Severity Index 75% response at observational point 2From Baseline up to Week 21

The Psoriasis Area Severity Index (PASI75) response assessments are based on at least 75 % improvement in the PASI score from Baseline. The PASI score is a measure of the average redness, thickness, and scaliness of the psoriatic skin lesions with a score of 0 (clear) to 4 (very marked).

Secondary Outcome Measures
NameTimeMethod
Change from Baseline in Dermatology Life Quality Index score at observational point 2From Baseline up to Week 21

The Dermatology Life Quality Index (DLQI) consists of questions concerning patients' perception of the impact of skin diseases on different aspects of their health-related quality of life over the last week. The DLQI score ranges from 0 to 30 with higher scores indicating lower health-related quality of life (HRQoL).

Change from Baseline in Dermatology Life Quality Index score at observational point 4From Baseline up to Week 56

The Dermatology Life Quality Index (DLQI) consists of questions concerning patients' perception of the impact of skin diseases on different aspects of their health-related quality of life over the last week. The DLQI score ranges from 0 to 30 with higher scores indicating lower health-related quality of life (HRQoL).

Percentage of patients achieving Psoriasis Area Severity Index 75% response at observational point 4From Baseline up to Week 56

The Psoriasis Area Severity Index (PASI75) response assessments are based on at least 75 % improvement in the PASI score from Baseline. The PASI score is a measure of the average redness, thickness, and scaliness of the psoriatic skin lesions with a score of 0 (clear) to 4 (very marked).

Percentage of patients achieving Psoriasis Area Severity Index 90% response at observational point 2From Baseline up to Week 21

The Psoriasis Area Severity Index (PASI90) response assessments are based on at least 90 % improvement in the PASI score from Baseline. The PASI score is a measure of the average redness, thickness, and scaliness of the psoriatic skin lesions with a score of 0 (clear) to 4 (very marked).

Percentage of patients achieving Psoriasis Area Severity Index 90% response at observational point 4From Baseline up to Week 56

The Psoriasis Area Severity Index (PASI90) response assessments are based on at least 90 % improvement in the PASI score from Baseline. The PASI score is a measure of the average redness, thickness, and scaliness of the psoriatic skin lesions with a score of 0 (clear) to 4 (very marked).

Trial Locations

Locations (79)

Ps0026 529

🇩🇪

Gladbeck, Germany

Ps0026 518

🇩🇪

Karlsruhe, Germany

Ps0026 532

🇩🇪

Bogen, Germany

Ps0026 902

🇬🇧

Bradford, United Kingdom

Ps0026 914

🇬🇧

Glasgow, United Kingdom

Ps0026 911

🇬🇧

Kingston Upon Thames, United Kingdom

Ps0026 506

🇩🇪

Düren, Germany

Ps0026 102

🇧🇪

Leuven, Belgium

Ps0026 104

🇧🇪

Namur, Belgium

Ps0026 209

🇨🇦

London, Canada

Ps0026 107

🇧🇪

Bruxelles, Belgium

Ps0026 110

🇧🇪

Maldegem, Belgium

Ps0026 103

🇧🇪

Brussels, Belgium

Ps0026 409

🇫🇷

Poitiers, France

Ps0026 407

🇫🇷

Toulon, France

Ps0026 512

🇩🇪

Bielefeld, Germany

Ps0026 525

🇩🇪

Dresden, Germany

Ps0026 203

🇨🇦

St- John's, Canada

Ps0026 204

🇨🇦

Winnipeg, Canada

Ps0026 403

🇫🇷

Rennes, France

Ps0026 302

🇨🇿

Uherske Hradiste, Czechia

Ps0026 516

🇩🇪

Merzig, Germany

Ps0026 527

🇩🇪

München, Germany

Ps0026 515

🇩🇪

Nürnberg, Germany

Ps0026 807

🇪🇸

Badalona, Spain

Ps0026 714

🇮🇹

Bologna, Italy

Ps0026 603

🇬🇷

Athens, Greece

Ps0026 608

🇬🇷

Patras, Greece

Ps0026 604

🇬🇷

Thessaloniki, Greece

Ps0026 501

🇩🇪

Potsdam, Germany

Ps0026 610

🇬🇷

Athens, Greece

Ps0026 511

🇩🇪

Quedlinburg, Germany

Ps0026 505

🇩🇪

Remscheid, Germany

Ps0026 609

🇬🇷

Athens, Greece

Ps0026 711

🇮🇹

Brescia, Italy

Ps0026 706

🇮🇹

L'aquila, Italy

Ps0026 809

🇪🇸

Barcelona, Spain

Ps0026 804

🇪🇸

Pontevedra, Spain

Ps0026 701

🇮🇹

Napoli, Italy

Ps0026 916

🇬🇧

Hertfordshire, United Kingdom

Ps0026 915

🇬🇧

Wakefield, United Kingdom

Ps0026 212

🇨🇦

Toronto, Canada

Ps0026 205

🇨🇦

Waterloo, Canada

Ps0026 519

🇩🇪

Leipzig, Germany

Ps0026 517

🇩🇪

München, Germany

Ps0026 109

🇧🇪

Mons, Belgium

Ps0026 201

🇨🇦

Markham, Canada

Ps0026 208

🇨🇦

London, Canada

Ps0026 210

🇨🇦

Newmarket, Canada

Ps0026 301

🇨🇿

Praha 5, Czechia

Ps0026 303

🇨🇿

Praha 1, Czechia

Ps0026 408

🇫🇷

Amiens Cedex, France

Ps0026 404

🇫🇷

Lorient, France

Ps0026 521

🇩🇪

Freiburg, Germany

Ps0026 523

🇩🇪

Hamburg, Germany

Ps0026 530

🇩🇪

Memmingen, Germany

Ps0026 537

🇩🇪

Magdeburg, Germany

Ps0026 601

🇬🇷

Chaidari, Greece

Ps0026 606

🇬🇷

Larissa, Greece

Ps0026 607

🇬🇷

Pireas, Greece

Ps0026 605

🇬🇷

Thessaloniki, Greece

Ps0026 707

🇮🇹

Bari, Italy

Ps0026 702

🇮🇹

Genova, Italy

Ps0026 709

🇮🇹

Roma, Italy

Ps0026 710

🇮🇹

Firenze, Italy

Ps0026 712

🇮🇹

Catania, Italy

Ps0026 713

🇮🇹

Roma, Italy

Ps0026 704

🇮🇹

San Donato Milanese, Italy

Ps0026 715

🇮🇹

Torino, Italy

Ps0026 708

🇮🇹

Torrette DI Ancona, Italy

Ps0026 812

🇪🇸

Barcelona, Spain

Ps0026 818

🇪🇸

Vigo, Spain

Ps0026 806

🇪🇸

Sant Joan Despí, Spain

Ps0026 909

🇬🇧

Dunfermline, United Kingdom

Ps0026 905

🇬🇧

Leeds, United Kingdom

Ps0026 904

🇬🇧

Newcastle Upon Tyne, United Kingdom

Ps0026 908

🇬🇧

York, United Kingdom

Ps0026 901

🇬🇧

Salford, United Kingdom

Ps0026 101

🇧🇪

Bruxelles, Belgium

© Copyright 2025. All Rights Reserved by MedPath